The authors regret in this article published in Journal of Interventional Medicine, the current order of references is not correct, and the correct reference order is now attached.
-
1.
Bertino G, Demma S, Ardiri A et al. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int. 2015; 2015: 731469.
-
2.
Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012; 262(1):43–58.
-
3.
Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008; 48(supp-S1):S20–S37.
-
4.
Ayaru L, Pereira SP, Alisa A et al. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol. 2007; 178(3):1914–1922.
-
5.
Mizukoshi E, Yamashita T, Arai K et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology. 2013; 57(4):1448–1457.
-
6.
Mizukoshi E, Yamashita T, Arai K et al. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Immunol Immunother. 2016; 65(6):715–725.
-
7.
Jin AO, Yue-Wei Z. Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research. J Interv Radiol. 2011; 18(3):229–234.
-
8.
Kamran AU, Liu Y, Li FE et al. Transcatheter arterial chemoembolization with gelatin sponge microparticles treated for BCLC stage B hepatocellular carcinoma: a single center retrospective study. Medicine. 2015; 94(52):e2154.
-
9.
Zhou J, Liu Y, Ren Z et al. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: initial clinical experience. J Cancer Res Ther. 2017; 13(5):767–772.
-
10.
Wu Q, Qin SK, Teng FM et al. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells. J Hematol Oncol. 2010; 3(1):43.
-
11.
Wang N, Lv YZ, Xu AH et al. Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma. Asian Pac J Cancer Prev. 2014; 15(2):647–650.
-
12.
Lencioni R. New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma. Clin Canc Res Off J Am Assoc Canc Res. 2013; 19(6):1312–1314.
-
13.
Dong W, An G, Xie S et al. The clinical and prognostic significance of CD14+HLA-DR-/low, myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. Tumour Biol. 2016; 37(8):10427–10433.
-
14.
Wan S, Kuo N, Kryczek I et al. Myeloid cells in hepatocellular carcinoma. Hepatology. 2015; 62(4):1304–1312.
-
15.
Bronte V, Brandau S, Chen SH et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016; 7:12150–12159.
-
16.
Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162–174.
-
17.
Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011; 32(1):19–25.
-
18.
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12(4):253–268.
-
19.
Heimbach J, Kulik LM, Finn R et al. Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358–380.
-
20.
Omata M, Lesmana LA, Tateishi R et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4(2):439–474.
-
21.
Han KH, Kudo M, Ye SL et al. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 2015; 81(Suppl.1):158–164.
-
22.
Han Kichang, Kim Jin Hyoung. Transarterial chemoembolization in hepatocellular carcinoma treatment: barcelona clinic liver cancer staging system. World J Gastroenterol. 2015; 21(36):10327–10335.
-
23.
Song L, Ran-Ran M, Yue-Wei Z. TACE combined with dendritic cells for the treatment of hepatic cancers: its influence on patient's immune function. J Interv Radiol. 2014; 23(2):181–184.
-
24.
Zhi-Zhong R, Ying L, Yuan-Xun Y et al. Postoperative changes and its significance of Treg cells in peripheral blood after GSMs- TACE treatment for large hepatocellular carcinoma in 15 patients. J Interv Radiol. 2018; 27(12):1151–1154.
-
25.
Chang CJ, Yang YH, Chiu CJ et al. Targeting tumor-infiltrating Ly6G+myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. Int J Cancer. 2018; 142(9):1878–1889.
-
26.
Jiang N, Xing YF, Hu B et al. Endoplasmic reticulum stress induced Lox-1+CD15+polymorphonuclear myeloid-derived suppressor cells in hepatocellular carcinoma. Immunology. 2017; 154(1):144–155.
-
27.
Weber R, Fleming V, Hu X et al. Myeloid-derived suppressor cells hinder the anticancer activity of immune checkpoint inhibitors. Front Immunol. 2018; 9:1310–1318.
-
28.
Guo B, Xie N, Wang Y. Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis. Bull Du Canc. 2015; 102(3):204–212.
-
29.
Hoechst B, Ormandy LA, Ballmaier M et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008; 135(1):234–243.
-
30.
Moehler M, Göpfert K, Outlook Lenz HJ. Immunotherapy in gastrointestinal carcinoma - innovative strategies. Oncol Res Treat. 2018; 41(5):313–315.
The authors would like to apologise for any inconvenience caused.